Qualigen Therapeutics, Inc. QLGN · Stock Open Qualigen Therapeutics, Inc. in new tab
Qualigen Therapeutics, Inc. Analysis (QLGN)
Is Qualigen Therapeutics, Inc. a good investment? Qualigen Therapeutics, Inc. (QLGN) is currently trading at 3.21 USD.
In terms of valuation, the stock trades at a P/E ratio of 1.13. This relatively low multiple may signal that Qualigen Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Qualigen Therapeutics, Inc. is expected to release its next earnings report on Aug. 18, 2026. The market consensus estimate for Forward EPS is -1.00.
Investor FAQ
Does Qualigen Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Qualigen Therapeutics, Inc.?
Qualigen Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 18, 2026. The company currently has a trailing EPS of 2.85.
Company Profile
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
| Split Date | Split Ratio to 1 |
|---|---|
| March 23, 2018 | 1:10 |
| May 26, 2020 | 1:25 |
| Nov. 23, 2022 | 1:10 |
| Nov. 5, 2024 | 1:50 |
Community Discussion